AUTL News and Press, Autolus Therapeutics plc From 04/25/22

LONDON, April 25, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its first quarter 2022 financial results and operational highlight...

The following slide deck was published by Autolus Therapeutics plc in conjunction with this event. For further details see: Autolus Therapeutics (AUTL) Presents at the American Association for Cancer Research Annual Meeting 2022 - Slideshow

Autolus Therapeutics plc (NASDAQ:AUTL) traded at a new 52-week high today of $53.24. This new high was reached on above average trading volume as 30.9 million shares traded hands, while the average 30-day volume is approximately 282,000 shares. In the past 52 weeks, Autolus Therapeutics ...

LONDON, March 31, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that the European Medicines Agency (EMA) has granted obe-cel, Autolus’ leading C...

- Wells Fargo Annual Biotech Forum on April 12 and 13 - - 21st Annual Needham Virtual Healthcare Conference on April 14 at 8:45am ET - - 14 th Kempen Life Sciences Conference on April 21 - presentation time to be confirmed on the Autolus website - LONDON, March 29, 2022 (G...

Autolus Therapeutics plc (AUTL) Q4 2021 Earnings Conference Call March 10, 2022 08:30 AM ET Company Participants Lucinda Crabtree - Senior Vice President, Finance Christian Itin - Chief Executive Officer Andrew Oakley - Chief Financial Officer Conference Call Participants Gil Blum - Needham &...

The following slide deck was published by Autolus Therapeutics plc in conjunction with their 2021 Q4 earnings call. For further details see: Autolus Therapeutics plc 2021 Q4 - Results - Earnings Call Presentation

Autolus Therapeutics press release (NASDAQ:AUTL): FY GAAP EPS of -$1.97 misses by $0.08. Revenue of $2.33M (+35.5% Y/Y) misses by $4.87M. “We rounded off the 2021 financial year announcing a collaboration with Blackstone Life Sciences, adding $150M in capital with an additional $100M i...

LONDON, March 10, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced its operational and financial results for the fourth quarter and full year ended Decemb...

Autolus Therapeutics (NASDAQ:AUTL) is scheduled to announce Q4 earnings results on Thursday, Mar. 10, before market open. The consensus EPS estimate is -$0.36 and the consensus revenue estimate is $5.85M. Over the last 2 years, AUTL has beaten EPS estimates 63% of the time and has beaten reve...